3SBio Inc. (HKG:1530)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 64.44B |
| Revenue (ttm) | 9.94B |
| Net Income (ttm) | 2.58B |
| Shares Out | 2.50B |
| EPS (ttm) | 1.05 |
| PE Ratio | 24.55 |
| Forward PE | 8.86 |
| Dividend | 0.25 (0.97%) |
| Ex-Dividend Date | Jul 21, 2025 |
| Volume | 6,921,354 |
| Average Volume | 24,217,708 |
| Open | 25.90 |
| Previous Close | 25.80 |
| Day's Range | 25.16 - 25.90 |
| 52-Week Range | 5.60 - 36.80 |
| Beta | 0.74 |
| RSI | 33.45 |
| Earnings Date | Mar 20, 2026 |
About 3SBio
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex... [Read more]
Financial Performance
In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.
Financial numbers in CNY Financial StatementsNews
3SBio Sells Shares, Divests Subsidiary To Boost Capital
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio is proactively b...
China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline
Chinese drug maker 3SBio plans to raise HK$3.12 billion (US$401 million) by selling a 4.14 per cent stake in the company to fund clinical research in China and the US and expand the global reach of it...
3SBio spin-off Mandi banks on hair-loss and weight-loss drugs in Hong Kong IPO
Mandi, the Alibaba Health-backed consumer healthcare arm being spun off from mainland drug maker 3SBio, filed for an initial public offering in Hong Kong on Friday, betting that its market-leading min...
Innovent's License Deal Fails To Excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $ 11.4 billion, pocketing a big downpayment, so why did its stock price fall? Key Takeaways: Innovent and it...
Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug
Pfizer and 3SBio have completed a licensing agreement that grants the US pharmaceutical giant worldwide rights to sell the Hong Kong-listed firm’s cancer drug, marking the largest deal ever for a sing...
Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega deal for righ...
Pfizer Thinks Bigger With 3SBio Deal
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2211058632-c248e750b38444ada4b367316e67f205.jpg)
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China
Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.
Pfizer strikes deal with China's 3SBio to license cancer drug
CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news.
Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal
Pfizer Inc. (NYSE: PFE) announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc. ‘s bispecific antibody SSGJ-707 in a deal potentially worth up to $6 billion. The agree...